VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Símbolo de cotizaciónVNRX
Nombre de la empresaVolitionRX Ltd
Fecha de salida a bolsaFeb 06, 2015
Director ejecutivoButera (Salvatore Thomas)
Número de empleados85
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 06
Dirección1489 West Warm Springs Road
CiudadHENDERSON
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal89014
Teléfono17024251561
Sitio Webhttps://volition.com/
Símbolo de cotizaciónVNRX
Fecha de salida a bolsaFeb 06, 2015
Director ejecutivoButera (Salvatore Thomas)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos